Ratings Dermapharm Holding SE

Equities

DMP

DE000A2GS5D8

Market Closed - Xetra Other stock markets 11:35:03 2024-04-18 am EDT			5-day change	1st Jan Change
31.8 ^EUR	-0.47%		-5.50%	-24.89%

Apr. 04	DERMAPHARM : Berenberg keeps its Buy rating	ZD
Mar. 28	Dermapharm Holding SE Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The group shows a rather high level of debt in proportion to its EBITDA.
For the last few months, analysts have been revising downwards their earnings forecast.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
DERMAPHARM HOLDING SE	-24.89%	1.83B	B-
ELI LILLY AND COMPANY	+27.97%	676B	C+
NOVO NORDISK A/S	+23.58%	554B	B
JOHNSON & JOHNSON	-7.02%	349B	C+
MERCK & CO., INC.	+14.85%	318B	B-
ABBVIE INC.	+6.25%	291B	C+
ASTRAZENECA PLC	+2.96%	210B	B+
NOVARTIS AG	-0.41%	204B	B-
ROCHE HOLDING AG	-10.02%	194B	A+
PFIZER, INC.	-11.81%	144B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes